Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PHIBRO ANIMAL HEALTH CORPPAHC · Entity 4671 | Director | May 29, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PHIBRO ANIMAL HEALTH CORP
Report date May 29, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 41,459 |
Reported balance
After 2026-05-29 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-29 · Purchase · Acquired 10,000 · Balance 41,459 F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $31.66 to $31.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range. F2: Includes 1,459 shares acquired under a dividend reinvestment plan sponsored by the Reporting Person's broker. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $31.66 to $31.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range.
F2: Includes 1,459 shares acquired under a dividend reinvestment plan sponsored by the Reporting Person's broker.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2026 Filed Jun 2, 2026 22:56 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | PurchaseClass A Common Stock | 10,000 | $31.77 | $317,700.00 |
DisclosureSEC source: 0001104659-26-069604 · tm2616591-1_4seq1.xml · nonDerivative · entry 1 CORCORAN E THOMAS · CIK 0001191763 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,459 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $31.66 to $31.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range. F2 · balance_after: Includes 1,459 shares acquired under a dividend reinvestment plan sponsored by the Reporting Person's broker. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 21:15 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | PurchaseClass A Common Stock | 5,000 | $22.10 | $110,500.00 |
DisclosureSEC source: 0001104659-25-017440 · tm257506-1_4seq1.xml · nonDerivative · entry 1 CORCORAN E THOMAS · CIK 0001191763 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.02 to $22.11. The Reporting Person undertakes to provide to the Issuer, any security holders of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within this range. Read SEC document |
| September 04, 2024 Filed Sep 6, 2024 20:34 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | PurchaseClass A Common Stock | 5,000 | $20.02 | $100,100.00 |
DisclosureSEC source: 0001104659-24-097763 · tm2423503-1_4seq1.xml · nonDerivative · entry 1 CORCORAN E THOMAS · CIK 0001191763 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.89 to $20.20. The Reporting Person undertakes to provide to the Issuer, any security holders of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within this range. Read SEC document |
| August 30, 2021 Filed Sep 2, 2021 00:00 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | PurchaseClass A Common Stock | 5,000 | $23.68 | $118,400.00 |
DisclosureSEC source: 0001104659-21-112162 · tm2126821d1_4.xml · nonDerivative · entry 1 CORCORAN E THOMAS · CIK 0001191763 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| August 30, 2019 Filed Sep 5, 2019 01:53 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | PurchaseClass A Common Stock | 5,000 | $21.21 | $106,050.00 |
DisclosureSEC source: 0001144204-19-043491 · tv528900_form4.xml · nonDerivative · entry 1 CORCORAN E THOMAS · CIK 0001191763 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.